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Abstract
Human parvovirus 4 (PARV4) has been detected in blood and tissue samples from HIV/AIDS patients who are
injecting drug users and we have reported PARV4 co-infection of hepatitis B or hepatitis C virus (HBV, HCV)
infected individuals. In this study, we have investigated the consequences of co-infection with PARV4 for HBV
infected individuals.
The aim of this study was to investigate the consequences of co-infection with PARV4 for HBV infected
individuals.
Serum samples from healthy controls and HBV infected subjects were retrieved from Shanghai Center for
Disease Control and Prevention Sample Bank. HBV genotypes were determined and sequences compared with
reference sequences to derive phylogeny trees. All samples were tested for PARV4, parvovirus B19 and HCV;
serum alanine transaminase (ALT) in chronic HBV patients was used as an indicator of disease severity. Relevant
cytokines were measured in sera from healthy controls and HBV carriers.
HBV infected subjects had higher prevalence of PARV4 compared to healthy controls. PARV4 prevalence was
not associated with HBV genotype, negatively correlated with serum HBV DNA, but positively correlated with serum
ALT level. Additionally, serum IL-8 was up-regulated in HBV carriers co-infected with PARV4.
Co-infection with PARV4 may increase the risk of liver disease in HBV patients through up-regulation of
inflammatory cytokines, but the underlying mechanism remains to be elucidated.
Keywords: Parvovirus 4; Hepatitis B virus; HBV-parvovirus co-
infection
Introduction
Parvoviruses are non-enveloped viruses with linear, single-stranded
DNA genomes and among the smallest of the animal DNA viruses [1].
Human Parvovirus 4 (PARV4) was identified in 2005 [2]; prior to that,
parvovirus B19 was the only known human pathogenic parvovirus.
The pathogenic mechanisms of PARV4 remain un-defined.
PARV4 DNA has been detected in blood samples from cadavers of
hepatitis C virus (HCV) RNA positive injecting drug users [3] and
liver tissues [4] of patients with chronic HCV infection. We have
previously observed an association between PARV4 infection and
HCV or hepatitis B virus (HBV) infection [5]. Parvovirus B19 is
associated with acute hepatitis and may cause a wide spectrum of
clinical complications in immunocompetent patients and in pregnant
women with primary infection [6]. Sharing 30% nucleotide identity
with B19, PARV4 might also be able to cause clinical complications in
infected subjects.
High PARV4 prevalence has been detected in HIV, HCV and HBV
infected individuals. Little is known about clinical features that
accompany co-infection of PARV4 [5, 7, 8] in at-risk population.
Recently PARV4 was linked to encephalitis [9] and symptoms such as
pharyngitis, vomiting, and arthralgias were observed in the individuals
with PARV4 [2]. Similar to Cytomegalovirus (CMV) and parvovirus
B19 (B19), PARV4 antigen persists in the host organ[10] and PARV4
shows greater resistance to pasteurization than B19 [11]. As a common
agent co-infection with other pathogens, PARV4 may have an more
important impact on clinical disease than B19. Simmons and his
colleagues observed no correlations between PARV4 serostatus and
HCV outcomes, but a significant association between PARV4
serostatus and early HIV-related symptom [12]. Our previous study
found a significant higher PARV4 seroprevalence in HBV and HCV
infected persons in Shanghai. But due to limitations of the previous
study we did not investigate the clinical disease of the PARV4 infected
HBV and HCV infections.
In this study we confirmed the prevalence of PARV4 DNA in the
healthy and HBV infected subjects in Shanghai, as well as the
association between PARV4 and HBV infection. To analyze the
consequences of PARV4 co-infection.in HBV infected individuals in
Shanghai, we investigated the association between PARV4 prevalence
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and serum ALT concentration, as well as the association between
PARV4 prevalence and HBV DNA concentration. We also determined
and analyzed the serum levels of inflammatory cytokines of the study
subjects.
Results
HBV genotype C dominates in Shanghai and is associated
with higher ALT levels.
HBV genotype was determined in 194 serum samples with the
commercial genotype kit. Overall, the genotyping results showed that
36.1% (70/194, 95%CI:29.3-43.3%) of HBV isolates belonged to B
genotype, 57.2% (111/194,95%CI:49.9-64.3%) belonged to C genotype,
1.5% (3/194,95%CI:0.3-4.5%) were mixed B and C genotype;
genotypes of the remaining 5.2% (10/194, 95%CI:2.5-9.3%）of isolates
could not be determined.
Sequence analysis of a subset of isolates (19 B genotype, 19 C
genotype, 3 B/C mixed type and 4 undefined isolates) showed that the
commercial kit correctly identified the 19 B genotype and 19 C
genotype isolates, while the three isolates classed as B/C mixed
genotype belonged to C genotype and the four isolates with undefined
genotype belonged to B genotype. Our data suggest that although the
commercial kit can be used for genotyping of HBV, those isolates
identified as B/C mixed or undefined type by the commercial kit
should be further analysed by sequencing.
46.0% (52/113, 95%CI:36.6-55.6%) of HBV carriers were infected
with HBV genotype B and 51.3% (58/113, 95%CI:41.7-60.8%) were
infected with HBV genotype C, p=0.432. Of the chronic HBV patients,
65.4% (53/81, 95%CI:54.0-75.7%) were infected with HBV genotype C
and 22.2% (18/81, 95%CI:13.7-32.8%) with HBV genotype B. The data
suggest that HBV C genotype is dominant in Shanghai and is
associated with disease progression in HBV infected subjects.
The complete genome sequences of 19 B and 17 C genotype isolates
were generated and submitted to Genbank (accession number JX
661485 to JX 661474) and with reference sequences downloaded from
Genbank, were used to build a phylogenetic tree （see supplement
figure 1）. All virus isolates belonged to B or C genotypes, no other
genotypes were identified.
The serum HBV DNA load of the chronic HBV patients infected
with genotype B (1.08x108; 95%CI, 2.72x105-4.44x109) or C viruses
(9.75x108; 95%CI, 3.05x106-3.70x1010) were similar (t test, p=0.402).
The serum ALT levels of the chronic HBV patients infected with
genotype C viruses (258.8 U/l,95%CI:101.6-420.8 U/l) were
significantly higher than those infected with genotype B viruses (43.3
U/l, 95%CI:29.3-59.7 U/l, t test, p=0.012, see Figure 1A). Serum ALT
levels did not correlate with serum HBV DNA load in chronic HBV
patients (r(coefficient of correlation)=0.011, p=0.387, Figure 1B). Our
data suggest that HBV genotype C may cause severe liver damage in
chronic patients but this may not be through direct damage by the
virus.
Supplement Figure 1: Phylogenetic tree of HBV sequences from
HBV infected subjects in Shanghai. The whole genome sequences
of the 45 isolates were determined by Biosune using 4 pairs of
previously reported primers [34]. Sequences were edited by Seqman
and ContigExpress, resulting in whole genome sequences of 36
isolates. The 36 sequences were used to construct a phylogenetic
tree with MEGA 5. To facilitate phylogenetic analysis, reference
sequences for the eight HBV genotypes (A, B, C, D, E, F, G, H) were
downloaded from GenBank (Genbank accession numbers
AB076678, AB126580, AB010291, AB033554, EF134945, EF134946,
EU939562, AB112063, EU939647, GQ377563, AB049609,
AB033559, AB126581, AB091255, AB106564, AB166850,
AY090459, AB056513, AB064310, AB205010 and AY090460). The
nucleotides sequence of the entire genome of HBV were amplified,
sequenced and analyzed using. Bootstrap value are given at the
node of each branch (1000 replicates). Viruses from HBV carriers
were defined as SHCA with respective numbers, such as SHCA1,
SHCA2， SHCA4， SHCA6， SHCA8， SHCA13， SHCA17，
SHCA18 ， SHCA23 ， SHCA24 ， SHCA29 ， SHCA31 ，
SHCA32 ， SHCA37 ， SHCA46 ， SHCA49 ， SHCA53 ，
SHCA56 ， SHCA59 ， SHCA62 ， SHCA66 ， SHCA69 ，
SHCA75，SHCA84，SHCA91，SHCA92 and SHCA99. Those
sequences from chronic HBV patients were named as SHCR, such
as SHCP3, SHCP9, SHCP11, SHCP22, SHCP23, SHCP26, SHCP31,
SHCP34, SHCP38 and SHCP39. Sequences of 8 different HBV
genotype viruses (with Genbank code) were downloaded from
Genbank and analyzed as the reference viruses. The dashed circles
in black represent sequences of HBV references genotype of A、
B、C、D、E、F、G and H. The open circles represented viruses
from Shanghai.
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Figure 1: Serum ALT levels, HBV genotype and HBV DNA
concentration. Alanine transaminase (ALT) was assayed in sera
from chronic hepatitis B virus (HBV) patients using commercial
kits as described in Methods. Serum specimens of HBV antigen
(HBsAg) positive study subjects were tested for presence of HBV
DNA with Real Time PCR Quantitation kit (ZJ Bio-Tech,
Shanghai) using the Roche Light Cycler 480. HBV genotype was
determined with a commercial HBV genotype (B & C) detection
Real Time PCR kit (KL Bio-Tech, Shanghai) using the Roche Light
Cycler 480. Average ALT levels in the serum samples collected from
HBV B genotype infected subjects and HBV patients infected with
C genotype are shown. Significant difference between B genotype
and C genotype HBV infected patients is shown (χ2 test, p≤0.05). B.
Association between ALT levels and HBV DNA concentration in
the serum samples collected from chronic HBV patients were
analyzed by Pearson correlation r (coefficient of correlation) and p
value is indicated.
PARV4 Positive detection rate of HBV infected
subjects is higher than healthy controls.
To explore the PARV4 prevalence in HBV infected study subjects,
we tested for the presence of PARV4 DNA in sera from 50 healthy
controls, 92 HBV carriers and 70 chronic HBV patients. 16.0% (8/50,
95%CI:7.2-29.1%) of healthy controls and 31.5% (51/162, 95%CI:
24.1-40.0%) of HBV infected subjects were PARV4 DNA positive (MH
χ2=4.53, p=0.033, Figure 2A). The PARV4 DNA positive detection
rate was similar in HBV carriers (28.3%, 26/92, 95%CI:17.9-39.6%)
and chronic HBV patients (35.7%, 25/70, 95%CI:24.6-48.1%, MH
χ2=1.02, p=0.311, Figure 2C). There was no difference (MH χ2=1.75,
p=0.186, see Figure 2B) in serum PARV4 DNA prevalence between
subjects infected with HBV genotype B (23.2%, 13/56, 95%CI:
13.0-36.4%) or genotype C (33.8% 27/80, 95%CI:23.6-45.2%).
Abnormal liver function is related to higher PARV4
prevalence in chronic HBV patients.
To investigate the association between PARV4 prevalence and
serum ALT concentration, we categorized chronic HBV patients into 2
groups based on their serum ALT concentration. Patients with serum
ALT concentration lower than 40U/L were termed the Liver Function
Normal group; patients with serum ALT concentration higher than or
equal to 40U/L were termed the Liver Function Abnormal group.
Compared with the Liver Function Normal group (25%, 10/40, 95%CI:
12.7-41.2%), the Liver Function Abnormal group (50%, 15/30, 95%CI:
31.3-68.7%) had higher PARV4 prevalence (MH χ2=4.60, p=0.032,
Figure 2D). Our data show that co-infection with PARV4 is associated
with liver abnormality in chronic HBV patients.
Figure 2: HBV infected subjects have higher PARV4 prevalence
than healthy controls but PARV4 positive detection rate decreases
with increasing HBV DNA concentration. Parvovirus (PARV)
nested PCR was performed in all sera using the outer primers
PV4ORF1F and PV4ORF1R and the inner primers PV4NS1Fn2
and PV4NS1Rn2 as described in Methods. The PARV4 DNA
positive detection rate in the serum samples collected from HBV
infected subjects and healthy controls (A) or subjects infected with
HBV B or C genotype (B) or chronic HBV patients and HBV
carriers (C) are shown. Significant differences between study
groups (χ2 test, p≤0.05) are indicated. Data shown are percentage
±95% CI. (D) ALT was assayed in sera from chronic HBV patients
using the alanine aminotransferase Kit (UV-LDH Method) from
Kehua Cooperation, Shanghai). The PARV4 DNA positive
detection rate in serum samples collected from patients with serum
ALT concentration lower than 40U/l (the Liver Function Normal
group) and patients with serum ALT concentration higher than or
equal to 40U/l (the Liver Function Abnormal group) are shown.
Significant differences (χ2 test, p≤0.05) between 2 study groups are
indicated. (E) HBV DNA was determined in sera from HBsAg
positive study subjects. The PARV4 DNA positive detection rate in
serum samples negative for HBV DNA (serum HBV DNA
concentration ≤5×103 IU/ml); with Low HBV DNA (HBV DNA
concentration between 5×103 IU/ml and 5×108 IU/ml) and with
High HBV DNA (HBV DNA concentration ≥5×108 IU/ml) are
shown. The χ2 test for linear trend was used to analyze statistical
differences among the 3 groups and is indicated on the graph. Data
shown are mean±95% CI.
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PARV4 positive detection rate decreased with
increasing HBV DNA concentration.
HBV infected study subjects were categorized into 3 groups based
on their serum HBV DNA concentration. PARV4 prevalence in the
HBV DNA Negative group, Low HBV DNA group and High HBV
DNA group was 46.2% (12/26, 95%CI: 26.6-66.6%), 29.8% (37/124,
95%CI: 22.0-38.7%) and 16.7% (2/12, 95%CI: 2.1-48.4%), respectively.
When the High HBV DNA group was set as reference, the odds ratio
(OR) of the HBV DNA negative group and Low HBV DNA group
were respectively 2.13 and 4.29; suggesting that with the decrease of
the serum HBV DNA concentration, the PARV4 infection rate
increased, (χ2 for linear trend=3.92, p=0.047, see Figure 2E). Our data
suggest that patients with lower HBV virus load are more likely to be
co-infected with PARV4. HBV infection may, directly or indirectly,
inhibit the replication of co-infecting viruses like PARV4.
Serum IL-8 is up-regulated in HBV carriers when
compared to healthy controls.
Serum levels of IL-1, IL-6, IL-8, IL-10, IL-12, TNF-α were 3.08
pg/ml (95%CI: 1.82-4.33 pg/ml), 3.82 pg/ml (95%CI: 3.15-4.49 pg/ml),
41.48 pg/ml (95%CI: 26.52-64.85 pg/ml), 1.93 pg/ml (95%CI:1.39-2.46
pg/ml), 2.47 pg/ml (95%CI:1.59-3.34 pg/ml) and 1.64 pg/ml (95%CI:
1.05-2.22 pg/ml), respectively in healthy controls and 2.40 pg/ml
(95%CI:1.94-2.85 pg/ml), 3.17 pg/ml (95%CI: 2.66-3.68 pg/ml), 102.71
pg/ml (95%CI:60.39-174.66 pg/ml), 1.49 pg/ml (95%CI:1.13-1.85 pg/
ml), 2.21 pg/ml (95%CI:1.35-3.07 pg/ml) and 1.35 pg/ml (95%CI:0.45-
2.24 pg/ml), respectively in HBV carriers (Figure 3A). Compared with
healthy controls, serum IL-1 (p=0.236), IL-6 (p=0.161), IL-10
(p=0.181), IL-12 (p=0.724) and TNF-α (p=0.688) were unchanged, but
IL-8 (p=0.041) was markedly up-regulated in HBV carriers (Figure
3B).
There was no difference in serum levels of IL-1, IL-6, IL-8, IL-10,
IL-12 and TNF- α, (IL-1 (p=0.106), IL-6 (p=0.811), IL-8 (p=0.309),
IL-10 (p=0.705), IL-12 (p=0.379) and TNF-α (p=0.111), between HBV
carriers infected with B or C genotype virus (Figure 3CD).
Serum IL-8 is up-regulated in HBV carriers co-infected
with PARV4
Serum levels of IL-1, IL-6, IL-8, IL-10, IL-12, TNF-α were 2.41
pg/ml (95%CI:1.87-2.94 pg/ml), 2.91pg/ml (95%CI:2.47-3.37 pg/ml),
82.41 pg/ml (95%CI:69.09-108.35 pg/ml), 1.40 pg/ml (95%CI:1.03-1.78
pg/ml), 2.17 pg/ml (95%CI:1.23-3.11 pg/ml) and 1.72 pg/ml (95%CI:
0.59-2.84 pg/ml), respectively in HBV carriers not infected with
PARV4 and 2.62 pg/ml (95%CI:2.29-2.94 pg/ml), 3.74 pg/ml (95%CI:
3.08-4.39 pg/ml), 182.77 pg/ml (95%CI:153.98-221.23 pg/ml), 1.50
pg/ml (95%CI: 1.13-1.86 pg/ml), 2.58 pg/ml (95%CI:1.78 -3.39pg/ml)
and 0.90 pg/ml (95%CI: 0.56-1.25 pg/ml), respectively in HBV carriers
infected with PARV4.
There was no difference in the serum levels of IL-1, IL-6, IL-8,
IL-10, IL-12 and TNF- α IL-1 (p=0.636), IL-6 (p=0.083), IL-10
(p=0.775), IL-12 (p=0.618) and TNF- α (p=0.360), Figure 3E) between
HBV carriers with and without co-infection with PARV4. However,
HBV carriers co-infected with PARV4 displayed up-regulated serum
IL-8 (p=0.025) compared to HBV carriers without PARV4 infection
(Figure 3F).
Figure 3: Serum IL-8 is up-regulated in HBV carriers compared to
healthy controls and in HBV carriers co-infected with PARV4.
Serum levels of interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12 and
tumor necrosis factor (TNF)-α were assayed using a Human
Inflammatory Cytokine Cytometric Bead Array（CBA）kit as
described in Methods. Kruskal-Wallis H test was used to determine
the statistical differences between study groups, significant
differences (p<0.05) are indicated. Data presented are mean±95%
CI. Serum levels of IL-1, IL-6, IL-10, IL-12 and TNF-α in healthy
controls (white bars) and HBV carriers (grey bars). Serum levels of
IL-8 in healthy controls (white bars) and HBV carriers (grey bars).
Serum levels of IL-1, IL-6, IL-10, IL-12 and TNF-α in HBV
genotype C infected carriers (white bars) and HBV genotype B
infected carriers (grey bars). Serum levels of IL-8 in HBV genotype
C infected carriers (white bars) and HBV genotype B infected
carriers (grey bars). Serum levels of IL-1, IL-6, IL-10, IL-12 and
TNF-α in HBV carriers not co-infected with PARV4 (white bars)
and those co-infected with PARV4 (grey bars). Serum levels of IL-8
in HBV carriers not co-infected with PARV4 (white bars) and those
co-infected with PARV4 (grey bars).
The serum nucleic acid concentration of HCV and B19
in co-infected patients is low
Only 2 study subjects, both male, were positive for B19 DNA (Table
1). Both of them were diagnosed as chronic HBV patients; HBV DNA
load could be estimated in only one patient (1.8×105 IU/mL). The
serum B19 DNA concentration of the two HBV/B19 co-infected
patients was 6.7×104 and 8.0×104 IU/mL.
Similarly, only 2 study subjects were positive for HCV RNA (Table
1). One was male HBV carriers and the other was chronic HBV patient
with HBV DNA concentration of 3.4×105 and 1.8×105 IU/mL and
HCV RNA concentration of 5.0×104 and 5.3×104 IU/mL respectively.
None of the study subjects were positive for HBoV DNA.
Patient ID. CP10 CP21 CA78 CP37
Gender Male Male Male Male
Age 49 50 21 48
HBsAg Pos Pos Pos Pos
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HBeAg Pos Neg Neg Neg
HBV DNA (IU/mL) 1.8x105 Neg 3.4x105 1.8x105
HBV Genotype C / B C
HCV IgG Neg Neg Neg Neg
HCV RNA (IU/mL) Neg Neg 5.0x104 5.3x104
PARV4 DNA Pos Neg Pos Neg
B19 DNA (IU/mL) 6.7x104 8.0x104 Neg Neg
ALT (U/L) 52 12 10 31
Clinical Diagnosis Chronic HBV Chronic HBV Carrier ChronicHBV
Table 1: The characteristics of HBV infected study subjects co-infected
with B19 or HCV
Discussion
We have used serum samples from HBV carriers and chronic HBV
patients to analyze the consequences of PARV4 co-infection in HBV
infected individuals in Shanghai. Using phylogenetic analysis
combined with serological assays, we have shown that HBV genotype
C predominates in Shanghai and may cause more severe disease than
genotype B and that co-infection with PARV4 is associated with
increased liver damage in chronic patients. Previously, we have
reported that co-infection with PARV4 may not be associated with
increased disease severity in HBV patients [5]; this discrepancy with
our current findings is probably due to the different criteria used to
define HBV carriers and chronic patients in the two studies.
Previously, we defined chronic HBV patients as those positive for both
HBsAg and HBeAg, however, chronic HBV patients can be HBeAg
negative or positive [13]. In the current study, we have used strict
clinical criteria including liver biopsy, resulting in a more robust
differentiation of chronic HBV patients from HBV carriers. Similar to
our previous report, we found that HBV infected subjects had higher
prevalence of PARV4 infection compared to healthy subjects.
However, no difference in prevalence of PARV4 co-infection was
found between HBV carriers and chronic patients and between those
infected with HBV genotype B or genotype C.
Previous studies have suggested a significant correlation between
HBV and parvovirus B19 co-infection [14, 15] while PARV4 was
originally detected in a HBV infected patient, raising the possibility of
an association with HBV infection [2,16]. The frequency of PARV4
DNA detection was significantly higher among HBV infected subjects
than matched healthy controls, which is in agreement with our
previous study [5] and similar to results from a cohort of hemodialysis
and lung transplant patients [17]. There was no difference in PARV4
DNA positive rate between HBV carriers and chronic HBV patients as
we have reported previously [5]. There was also no association of HBV
genotype with PARV4 co-infection, with patients infected with
genotype B or C being equally affected. However, within the chronic
HBV patients group, the Liver Function Abnormal group had
markedly higher PARV4 prevalence than the Liver Function Normal
group, suggesting that co-infection with PARV4 may promote liver
damage in chronic HBV patients.
The current study also showed that with decreasing serum HBV
DNA levels, PARV4 infection rate increased gradually, and displayed a
dose-dependent trend (χ2 for linear trend of 3.99, p=0.046). Our data
suggest a reciprocal inhibition of infection and/or replication of HBV
and PARV4; this is consistent with a previous study showing that the
translation machinery of hepatocytes may be down-regulated after
infection with HCV, through the activity of the core protein [18].
Elucidation of the underlying mechanisms would require analyses of
liver biopsies from infected individuals, which was beyond the scope of
this study. In our study, the prevalence of HCV and B19 in HBV
infected subjects was similar (0.5%, 2/383). The serum nucleic acid
concentrations of HBV, HCV and B19 in co-infected patients were all
lower than 5×105 IU/ml, suggesting that the replication not only of
HBV but of HCV and B19 was suppressed to some extent in HBV co-
infected study subjects.
A recent study found that PARV4 infection elicits strong T cell
responses [19], while we have observed markedly higher serum IL-8
levels in HBV carriers co-infected with PARV4, a feature typically
associated with persistent, contained infections similar to
cytomegalovirus and human immunodeficiency virus -1 co-infection
[20]. Together, the findings suggest that persistence of PARV4 in
HBV/HCV infected individuals and the associated activated antiviral
T cell response, as well as the elevated serum IL-8 production may
contribute to disease pathogenesis.
Interestingly, we found a PARV4 seropositive detection rate of
16.0% (8/50) in healthy subjects in Shanghai. Previous findings have
suggested parenteral acquisition of PARV4 infections [8,21-23].
However, our current study, taken with similar studies showing
26.15% (51/195) of lots of source plasma pools from healthy donors in
Beijing were positive for PARV4 [24] and 16.7% to 17.6% PARV4 IgM
seropositivity in healthy adults in Taiwan [25] suggest that PARV4
may be transmitted through non-parenteral routes. Similar PARV4
prevalence has also been reported from Africa [26,27]; importantly,
there was no parenteral risk in either of the African studies, further
supporting this idea. Given the high prevalence of PARV4 DNA in
sera from healthy population, other nonparenteral transmission routes
may exist and need to be investigated.
HBV genotypes have distinct geographic distributions and maybe
associated with disease severity [28]. We found that more study
subjects were infected with HBV C genotype than B genotype. We also
found that genotypes B and C almost equally accounted for the HBV
carriers; but in chronic HBV patients genotype C accounted for 3
times more infections than the genotype B, suggesting that genotype
C, but not B, is associated with a more aggressive disease, paralleling
other studies within [29] and outside China [30]. HBV genotype C has
been reported to be more prevalent in southern China [30], more
frequent in patients with chronic HBV infection and hepatocellular
carcinoma (HCC) [29, 30], and associated with more severe liver
damage in HBeAg-negative patients [31]. In this context, HBV
genotype C may more readily cause liver damage and disease
progression in HBV infected patients.
HBeAg-negative patients with detectable HBV DNA have been
shown to have more severe liver damage [31] and elevated serum HBV
DNA level (≥10,000 copies/ml) is a strong risk predictor for HCC [32].
However, in our study serum HBV DNA load between genotype B and
C HBV patients was similar, consistent with another study which
suggested that viral genotypes may not have a direct influence on HBV
DNA levels [30]. There was no correlation of serum ALT levels with
HBV DNA load in chronic HBV patients suggesting that HBV may
not cause liver damage directly in chronic HBV patients.
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In conclusion, there was no association of HBV genotype with
PARV4 prevalence in co-infected subjects. PARV4 infection was
negatively correlated with serum HBV DNA concentration, but
positively related to serum ALT production in co-infected subjects.
Importantly, we found an association between serum IL-8 level and
PARV4 infection in HBV carriers. Co-infection with PARV4 in HBV
infected subjects may induce immune responses through up-
regulation of inflammatory cytokine production and contribute to
disease pathogenesis, but the underlying mechanisms still need to be
clarified.
Our study was a cross-sectional, retrospective assessment of a
limited number of HBV infected subjects and our ability to define the
interactions of PARV4 and HBV, as well as the subsequent clinical
outcomes was limited. A longitudinal study of PARV4 and HBV co-
infection would provide a better understanding of the effect of co-
infection on disease progression.
Methods
Study Groups
Serum samples of healthy control and HBV infected subjects were
retrieved from Shanghai Center for Disease Control and Prevention
(SCDC) sample bank. Two hundreds and fourteen serum samples of
patients who were clinically diagnosed as HBV carriers (113) or
chronic HBV patients (101) according to the case definition from the
Viral Hepatitis B Diagnostic Criteria from Ministry of Health of China
(WS299 2008) were retrieved. Chronic HBV patients were defined as
those who were positive for HBsAg ≥6 months, positive for serum
HBeAg or HBV DNA, with persistent or intermittent elevation in
ALT/AST levels; or those who were positive for HBsAg ≥6 months,
positive for serum HBeAg or HBV DNA, with liver biopsy showing
chronic hepatitis with moderate or severe necro-inflammation. HBV
carriers were defined as those positive for HBsAg ≥6 months, positive
or negative for serum HBeAg, serum HBV DNA ≤2,000 IU/ml,
persistently normal ALT/AST levels with liver biopsy showing absence
of significant hepatitis. At the same time we chose 50 serum samples
collected from healthy subjects in 2010 that were negative for both
anti-HCV IgM and HBsAg as the healthy controls.
Serological ELISA
Anti-HCV IgG and HBsAg were assayed in all serum samples and
HBeAg was assayed in all sera positive for HBsAg using commercial
ELISA kits (Diagnostic Kit for Anti-HCV IgG, HBsAg and HBeAg
from Kehua Cooperation, Shanghai) as described previously [5].
PARV PCR
The total DNA of each serum sample (200μl) was isolated and 60μl
of eluted nucleic acid used as template for PARV nested PCR using
published PCR primers and reaction conditions [33] as described
previously [5].
B19 and Bocavirus Real-time PCR
Human Parvovirus (B19) Real Time PCR kit and human bocavirus
(HBoV) Real Time PCR kit (Both from Shanghai ZJ Bio-Tech Co.,
Ltd., People’s Republic of China) were used to perform B19 and HBoV
real-time PCR respectively, in all sera.
HBV DNA /HCV RNA Test and ALT Assay
Serum specimens of HBsAg positive subjects were tested for
presence of HBV DNA and HCV RNA with Real Time PCR
Quantitation kit (ZJ Bio-Tech, Shanghai) using the Roche Light Cycler
480 (Roche, Switzerland). As per kit protocols, specimens with HBV
DNA ≤ 5×103 IU/ml are accepted as negative for HBV DNA;
specimens with results between 5×103 IU/ml and 5×108 IU/ml are
accepted as positive for HBV DNA; those with HBV DNA > 5×108
IU/ml need to be eluted and tested again. Therefore, we grouped study
subjects into 3 groups based on their HBV DNA concentration;
subjects with HBV DNA ≤ 5×103 IU/ml were defined as the HBV
DNA Negative group those with serum HBV DNA concentration >
5×103 IU/ml but ≤ 5×108 IU/ml were termed Low HBV DNA group;
those with serum HBV DNA concentration > 5×108 IU/ml were
termed High HBV DNA group.
ALT was assayed in sera from chronic HBV patients using a
commercial kit (UV-LDH Method, Kehua Cooperation, Shanghai).
Experiments were performed as per instructions; positive and negative
controls provided by the company were included in each test.
According to kit protocol, serological positivity was accepted at titers
≥40 U/l.
HBV Genotyping
HBV genotype was determined with a commercial HBV genotype
(B & C) detection Real Time PCR kit (KL Bio-Tech, Shanghai).
Experiments were performed as per instructions; strong positive
control for B/C, positive control for B, positive control for C and
negative controls provided by the company were included in each test.
The PCR was run on Roche Light Cycler 480. The results were
analyzed and interpreted according to kit protocols.
Sequencing and Phylogenetic Analysis
The presence of PARV in sera was confirmed by DNA sequencing
of amplification products. PCR amplicons from the position 1564 to
1724 of ORF1 were sequenced by Biosune using internal primers
(BioSune, Shanghai). Sequences were blasted in Genbank.
To confirm results from the commercial HBV genotype (B & C) kit,
we selected 19 sera from each of the groups identified as B or C, all 3
sera identified as mixed B/C, and 4 of the 10 sera where the genotype
was undefined (6 samples were insufficient for further genotyping).
The whole genome sequences of the 45 isolates were determined by
Biosune using 4 pairs of previously reported primers [34]. Sequences
were edited by Seqman and Contig Express, resulting in whole genome
sequences of 36 isolates. The 36 sequences were used to construct a
phylogenetic tree with MEGA 5. To facilitate phylogenetic analysis,
reference sequences for the eight HBV genotypes (A, B, C, D, E, F, G,
H) were downloaded from GenBank (Genbank accession numbers
AB076678, AB126580, AB010291, AB033554, EF134945, EF134946,
EU939562, AB112063, EU939647, GQ377563, AB049609, AB033559,
AB126581, AB091255, AB106564, AB166850, AY090459, AB056513,
AB064310, AB205010 and AY090460).
CBA Assays
Serum IL-1, IL-6, IL-8, IL-10, IL-12 and TNF-α levels were assayed
in sera from healthy controls and HBV carriers using a Human
Inflammatory Cytokine Cytometric Bead Array (CBA) kit (BD
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Biosciences, San Jose, CA, USA) as described previously [35]. The
means±95% confidence interval (CI) are shown.
Data Analysis
Data were processed by EpiInfo version 3.5. Differences between
nominal or ordinal variables were tested by the Mantel-Haenszel
(MH) χ2 test. Continuous numeric data were compared by t test or
nonparametric Kruskal-Wallis χ2 test. The χ2-test for linear trend was
employed to evaluate the relationship between serum HBV DNA load
and the PARV4 positive detection rate of the HBV infected study
subjects. Significance was accepted at p ≤0.05.
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